The New York Stock Exchange with a Hims & Hers Health, Inc banner is pictured as a person runs past in the Manhattan borough of New York City, New York, U.S., January 21, 2021. REUTERS/Carlo Allegri

Event overview

Hims & Hers plummets 16% after first-quarter loss, weak earnings guidance

Updated 13 hours ago
CNBC
Reuters
2 articles•2 sources
Summary

Hims & Hers reached a deal with Novo Nordisk in March to sell its 1 weight loss drug Wegovy on its platform. This cluster currently includes 2 articles from 2 sources.

What this means

This cluster currently includes 2 articles from 2 sources. Sources in this event include Reuters, CNBC.

Source coverage

Left / left-center

1

Center

1

Right / right-center

0

CNBC

CNBC

7/10
Leaning left

Factual: mostly-factual · Credibility: high

Reuters

Reuters

9/10
Balanced

Factual: very-high · Credibility: high

Original reporting (2)
Hims & Hers plummets 13% after first-quarter loss, weak earnings guidance
CNBC
CNBC
Leaning left
5/12/2026

Hims & Hers plummets 16% after first-quarter loss, weak earnings guidance

Hims & Hers reached a deal with Novo Nordisk in March to sell its GLP-1 weight loss drug Wegovy on its platform.

The New York Stock Exchange with a Hims & Hers Health, Inc banner is pictured as a person runs past in the Manhattan borough of New York City, New York, U.S., January 21, 2021. REUTERS/Carlo Allegri
Reuters
Reuters
Balanced
5/12/2026

Hims & Hers plunges as branded weight-loss drug pivot hits results

Shares of Hims & Hers ​Health fell 11% on Tuesday after the telehealth company's pivot to branded ‌weight-loss drugs drove up costs and led to a surprise loss in the first quarter.